Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 8, Issue 7, Pages 764-766Publisher
WILEY
DOI: 10.1016/j.ejheart.2006.10.001
Keywords
FIX-CHF-4; selective cardiac myosin activator; OPT-CHF
Categories
Ask authors/readers for more resources
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the Heart Failure Society of America meeting held in Seattle in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. Devices designed to improve cardiac contractility may have improved exercise tolerance, and quality of life in the FIX-CHF-4 study; however, uncertainties in trial interpretation exist. The results of a study reporting the first administration of the selective myosin activator CK-1827452 to human volunteers, support the initiation of clinical trials in heart failure patients. In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels. (c) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available